ID | Sides/mixture/volume | Pre-ONB | Post-ONB 3 days | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Tenderness over GON | Intensity (VAS) | Susceptibility to triggers | Hypoesthesia after ONB | % of pre-ONB pain | Intensity (VAS) | Susceptibility to triggers | Duration of improvement (days) | Response (≥50%) | Painful? | Side effects? | ||
TNP1 | 2× (40 mg L (1%); 4 mg D/5 ml) | Contralateral | 3/10 | 0/10 | Right+, left+ | 100 | 3/10 | 0/10 | 0 | – | – | + |
TNP2 | 2× (30 mg L; 4 mg D/2.5 ml) | Ipsilateral | 5/10 | 1/10 | Right−, left+ | 40/100a, # | 6/10 | 0/10 | 0 | – | – | + |
TNP3 | 2× (40 mg L (1%); 4 mg D/5 ml) | Ipsilateral contralateral | 10/10 | 9/10 | Right+, left+ | 40/100a | 8/10 | 10/10 | 0 | – | – | + |
TNP4 | 2× (40 mg L (1%); 4 mg D/5 ml) | None | 8/10 | 8/10 | Right+, left+ | 50 | 5/10 | 8/10 | 12§ | + | + | + |
TNP5_1 | 2× (30 mg L; 4 mg D/2.5 ml) | n.a. | 10/10 | 10/10 | Right+, left+ | <5% | 2/10 | 0/10 | 3 | + | – | + |
TNP5_2 | 2× (30 mg L; 4 mg D/2.5 ml) | Ipsilateral contralateral | 9/10 | 10/10 | Right+, left+ | 15 | 2/10 | 0/10 | 6 | + | – | – |
TNP6 | 2× (40 mg L (1%); 4 mg D/5 ml) | Ipsilateral | 9/10 | 5/10 | Right+, left+ | 40# | 4/10 | 0/10 | 4 | + | – | + |